{"id":837410,"date":"2025-04-15T08:50:10","date_gmt":"2025-04-15T12:50:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/"},"modified":"2025-04-15T08:50:10","modified_gmt":"2025-04-15T12:50:10","slug":"tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/","title":{"rendered":"Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia"},"content":{"rendered":"

<\/p>\n

Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia<\/b><\/p>\n

FREMONT, Calif.–(BUSINESS WIRE<\/a>)–
\nTivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod\u2122 for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 (TLR5) immunotherapy program Entolimod\u2122.\n<\/p>\n

\nNeutropenia is a condition characterized by lower-than-normal levels of neutrophils, a type of white blood cell essential for combating infections. Causes of neutropenia include chemotherapy and radiation treatments, chronic infection, autoimmune diseases, bone marrow disorders and aging.\n<\/p>\n

\nAccording to Data Bridge Market Research, the global Neutropenia market is estimated to exceed $20 billion by 2029.\n<\/p>\n

\nUnder the terms of the company\u2019s previously announced agreement with Statera Biopharma, Inc., Tivic secured a worldwide exclusive license for Entolimod\u2122 as a potential treatment for acute radiation syndrome, or ARS.\n<\/p>\n

\nTLRs are a class of protein that plays a key role in the innate immune system. We believe that Entolimod\u2019s mechanism of action provides unique, highly sought-after attributes in the treatment of a number of indications besides ARS and Neutropenia. Tivic also has the option to license three additional indications: Lymphocyte exhaustion, Immunosenescence, and chronic radiation syndrome.\n<\/p>\n

\n\u201cAs Tivic prepares for commercial-grade manufacturing of Entolimod, we see the opportunity to leverage that investment across more than one indication,\u201d explained Jennifer Ernst, CEO of Tivic Health. \u201cEntolimod and Entolasta have been the subject of more than 40 animal and human trials and $140 million of prior investment. Based on the prior development, we believe that this important immunotherapy drug is ready to advance through the final steps toward a biologics license application filing and potential FDA approval.\u201d\n<\/p>\n

Terms of the License Agreement<\/b><\/p>\n

\nAs previously announced, Tivic Health entered into a license agreement with Statera Biopharma, Inc. to acquire the exclusive worldwide license for the TLR5 agonist program Entolimod\u2122 for ARS as well as the option to acquire the exclusive worldwide license for certain additional indications.\n<\/p>\n

\nFuture payments under the agreement will be milestone-driven, ensuring alignment with the clinical and commercial success of the TLR5 program for the licensed indications. This structure allows Tivic to strategically manage investment while maximizing potential returns as the assets progress toward FDA approval and commercialization.\n<\/p>\n

About Tivic Health Systems, Inc.<\/b><\/p>\n

\nTivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health. Tivic Health\u2019s bioelectronic division is developing non-invasive medical devices that personalize key stimulation parameters for the vagus nerve to deliver meaningfully improved effects on measures of the autonomous nervous system compared to current treatments, which are often invasive, ineffective or both.\n<\/p>\n

\nTivic Health\u2019s biopharma program\u2019s lead product candidate is the TLR5 agonist, Entolimod\u2122, which is in late-stage studies to treat acute radiation syndrome (ARS). The FDA has granted Fast Track and Orphan Drug designation to Entolimod\u2122 for ARS. Tivic is also preparing to file an investigational new drug (IND) application and to initiate a phase 2 clinical study for the treatment of Neutropenia.\n<\/p>\n

\nTLRs are a class of protein that plays a key role in the innate immune system. We believe that Entolimod\u2019s mechanism of action provides unique, highly sought-after attributes in the treatment of indications in addition to ARS and Neutropenia. Tivic has the option to license three additional indications: Lymphocyte exhaustion, Immunosenescence, and chronic radiation syndrome.\n<\/p>\n

\nTivic Health already has an FDA-approved over-the-counter device, ClearUP\u00ae, that treats sinus pain and pressure and is available through online retailers and commercial distributors. For more information about Tivic Health, visit: https:\/\/ir.tivichealth.com<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nCertain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cforecast,\u201d \u201cestimate,\u201d \u201cexpect,\u201d and \u201cintend,\u201d among others. These forward-looking statements are based on Tivic\u2019s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the development of Tivic\u2019s product candidates; Tivic Health\u2019s interactions with and guidance from the FDA; the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of Tivic\u2019s product candidates; the company\u2019s need for, and ability to secure when needed, additional working capital; changes to the company\u2019s business strategy; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; substantial competition; and the company\u2019s ability to maintain its Nasdaq listing. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health\u2019s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading \u201cRisk Factors,\u201d as well as the company\u2019s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and the company undertakes no duty to update such information except as required by applicable law.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250415663561\/en\/<\/a><\/span><\/p>\n

Investor Contact Information:
\n<\/b>
Hanover International, Inc.
\n
ir@tivichealth.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Medical Devices FDA Clinical Trials Biotechnology Radiology Health Pharmaceutical Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia FREMONT, Calif.–(BUSINESS WIRE)– Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod\u2122 for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 (TLR5) immunotherapy program Entolimod\u2122. Neutropenia is a condition characterized by lower-than-normal levels of neutrophils, a type of white blood cell essential for combating infections. Causes of neutropenia include chemotherapy and radiation treatments, chronic infection, autoimmune diseases, bone marrow disorders and aging. According to Data Bridge Market … <\/p>\n

Continue reading “Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-837410","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia FREMONT, Calif.–(BUSINESS WIRE)– Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod\u2122 for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 (TLR5) immunotherapy program Entolimod\u2122. Neutropenia is a condition characterized by lower-than-normal levels of neutrophils, a type of white blood cell essential for combating infections. Causes of neutropenia include chemotherapy and radiation treatments, chronic infection, autoimmune diseases, bone marrow disorders and aging. According to Data Bridge Market … Continue reading "Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-15T12:50:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250415663561r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia\",\"datePublished\":\"2025-04-15T12:50:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\\\/\"},\"wordCount\":984,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250415663561r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\\\/\",\"name\":\"Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250415663561r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-04-15T12:50:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250415663561r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250415663561r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/","og_locale":"en_US","og_type":"article","og_title":"Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia - Market Newsdesk","og_description":"Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia FREMONT, Calif.–(BUSINESS WIRE)– Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod\u2122 for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 (TLR5) immunotherapy program Entolimod\u2122. Neutropenia is a condition characterized by lower-than-normal levels of neutrophils, a type of white blood cell essential for combating infections. Causes of neutropenia include chemotherapy and radiation treatments, chronic infection, autoimmune diseases, bone marrow disorders and aging. According to Data Bridge Market … Continue reading \"Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-15T12:50:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250415663561r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia","datePublished":"2025-04-15T12:50:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/"},"wordCount":984,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250415663561r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/","name":"Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250415663561r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-04-15T12:50:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250415663561r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250415663561r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-extends-its-worldwide-license-of-tlr5-agonist-entolimod-to-include-the-treatment-of-neutropenia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=837410"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837410\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=837410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=837410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=837410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}